Abstract Intercellular adhesion molecule-1 (ICAM-1), a cell adhesion molecule with a key role in inflammation and immunosurveillance, has been implicated in carcinogenesis by facilitating instability of the tumor environment. The K469E single nucleotide polymorphism (SNP) (G>A) affects the ICAM-1 mRNA splicing pattern; the alternatively spliced isoform (ICAM-1-S) lacks transmembrane and intracellular domain, which affects the structural and signal transduction properties. Moreover, the expression of ICAM-1 is transcriptionally regulated by p53, and this SNP has been shown to be related with apoptosis. PCR-RFLP analysis was used to assess the K469E SNP status comparatively in 203 non-small cell lung cancer patients and 175 healthy sexmatched controls. This SNP was examined in relation to tumor kinetic parameters 
evaluation and Tdt-mediated dUTP nick end labeling assay), p53 immunohistochemistry status, and clinicopathological data in patients with operable stages. Both the genotype and allele frequency did not differ significantly between patients and controls. However, patients with the AG/AA genotypes had worse survival (39 vs 45 months, p00.036) and tended to be present in advanced stages (p00.057). Moreover, the AG/ AA genotypes exerted a synergistic effect with aberrant p53 on tumor progression, while the GG genotype retained a better apoptotic index. The AG/AA genotypes correlated with worse survival and advanced stages probably due to defective immunosurveillance and apoptosis. These genetic backgrounds may confer a selective advantage for dissemination of tumor cells with high metastatic potential compared to GG genotype.
Introduction
Intercellular adhesion molecule-1 (ICAM-1) is a transmembrane glycoprotein belonging to the Ig superfamily of cell adhesion molecules [1] . ICAM-1 is constitutively expressed in cells involved in immune response, but may be induced in other cell types such as endothelial and epithelial cells. It plays a crucial role in cell-cell interaction and is a key modulator of inflammatory responses, as it facilitates leukocyte trafficking into inflammatory sites [1] . It is also required for the interaction of T lymphocytes with antigen-presenting cells as a costimulatory molecule for T cell activation [2, 3] . Moreover, ICAM-1 is involved in signal transduction after binding to β2 integrin ligands through activation of the mitogen-activated protein kinase and AP-1 pathways, known to regulate cell proliferation [1] .
Recently, it has been shown that ICAM-1 possibly contributes to tumorigenesis and metastasis [4, 5] . Binding of tumor cells to endothelial ICAM-1 [6] leads to autoupregulation of tumor ICAM-1 and more importantly to chemotaxis of tumor-associated macrophages and neutrophils that eventually facilitate loosening of adhesive contacts and breakdown of endovascular barriers, permitting tumor cell migration, neo-angiogenesis, and ultimately instability of the tumor environment [4, 5] . This mechanism is supported by studies showing that patients with increased ICAM-1 expression in tumors have more advanced stage of the disease [5, 7] and that administration of an anti-ICAM-1 antibody delays the growth of non-small cell lung cancer (NSCLC) tumors in mice with human xenografts [8] .
ICAM-1 exists also in a soluble form (sICAM-1), which in the lung is produced by either proteolytic cleavage of the full-length ICAM-1 (alveolar epithelial cells) or by alternative splicing (pulmonary microvascular endothelial cells) [9] and can modulate the course of the inflammatory process [10] . sICAM-1 is increased significantly in NSCLC patients compared to healthy individuals [11] , and its levels correlate with TNM stage [12] , overall survival [13] , and response to treatment [13] .
Polymorphisms in the ICAM-1 gene have been identified and have been suggested to have functional activity; among them, the non-synonymous g.1548A >G (K469E) single nucleotide polymorphism (SNP), located three bases upstream of the splicing site in exon 6, has been found to affect the splicing of ICAM-1 mRNA [14] . This splicing site produces either the full-length ICAM-1 (ICAM-1-L) or a truncated isoform (ICAM-1-S), which is soluble and has altered dimerization and signal transduction properties [1] ; the GG genotype is considered to produce the ICAM-1-S less efficiently than AG and AA genotypes [14] . The G allele has been associated with greater adhesion of leukocytes [15] , while the A allele with increased baseline serum sICAM-1 [16] . Moreover, it has been demonstrated that the GG genotype exhibits higher sensitivity to apoptosis compared to the AA genotype [14] , and ICAM-1 expression can be directly induced by p53 in an NF-kB-independent manner [17] .
The g.1548G>A (K469E) polymorphism has been studied in various types of malignancies with disparate conclusions [18] [19] [20] [21] [22] . To the best of our knowledge, this polymorphism has not been studied in NSCLC so far. Taking into consideration the above, the aim of our study was to examine the genotype and allele distribution of this SNP in NSCLC, as well as the relation between the presence of ICAM-1 genotypes alone or in combination with p53 status, with tumor growth parameters [proliferation (PI) and apoptotic indices (AI)] and clinicopathologic features in operable stages.
Materials and methods
Patients, tissue, and blood sample collection and study design Patients with histologically confirmed NSCLC of all stages and follow-up data between January 2003 and December 2008 were enrolled in this retrospective analysis. Blood samples for genotyping along with patient and demographic information (including age, sex, and smoking status) were collected from 112 patients with locally advanced and metastatic NSCLC and 175 matched healthy individuals (controls). The medical history of controls was free of malignancies, autoimmune diseases, and cardiothoracic problems. Moreover, we used frozen and formalin-fixed paraffin-embedded tissue material from 91 NSCLC patients, previously employed in other studies [23, 24] . Prior to biopsy collection, none of the patients had undergone any chemo-and/or radiotherapy, to avoid putative genomic instability effects. After surgery, all patients at the same stage underwent the same therapeutic approach. Tumors were staged according to the AJCC TNM staging system (seventh edition) [25] . Informed consent was obtained to collect followup data. The study was conducted according to the revised (1983) Helsinki Declaration of 1975 and was approved by the Ethics Committee of the University of Athens. Table 1 summarizes the clinicopathologic characteristics of the 203 patients and 175 controls enrolled in this study.
Molecular analysis
Genotyping of ICAM-1 gene K469E polymorphism DNA was extracted from peripheral blood mononuclear cells of the blood samples in EDTA using the QIAamp DNA Blood Extraction Kit (Qiagen) as per manufacturer's instructions. DNA was extracted from the tissue samples as previously described [24] .
The genotyping assay was performed by a PCR-RFLP method as previously described [26] . Specifically, forward primer 5′-GGAACCCATTGCCCGAGC-3′ and reverse primer 5′-GGTGAGGATTGCATTAGGTC-3′ were used to amplify a 267-bp fragment containing the polymorphic site. The PCR was performed in a total volume of 25 μl containing 150 ng of genomic DNA, 100 ng of each primer, 200 μΜ dNTPs, 2.5 μl 10× buffer (Invitrogen), 1.5 mM MgCl 2 , and 1 μl Taq polymerase (Invitrogen). The cycling conditions consisted of: one cycle of 1 min at 96°C, followed by 30 cycles of 20 s at 96°C, primer annealing at 64°C for 5n, extension at 72°C for 1 min, and finally extension at 72°C for 5 min. PCR products were then digested overnight at 60°C, using 5 units of the restriction enzyme BstUI (New England Bio-Labs) in a final volume of 25 μl, which is in excess to avoid partial digestion. Additional positive control reactions employed: (1) use of a plasmid vector with known BstUI restriction sites and (2) use of well-characterized GG samples in each set of digestions. The fragments were run on 2 % ethidium bromide-stained agarose gel and visualized under UV light. In the presence of the G allele, a BstUI restriction site is present, thus resulting in fragments of 170 and 97 bp, while in the presence of the allele A, only the uncut 267-bp PCR product is observed. The genotyping assay was performed in both tumor and matched adjacent normal tissues of each patient sample in order to identify possible loss of heterozygosity. Two authors independently reviewed the genotyping results, data entry, and statistical analyses.
TP53 automated sequence analysis
Additional automated sequencing TP53 gene sequencing analysis was performed on our NSCLC patients, as previously described [23, 24] .
Immunohistochemistry
Immunohistochemistry (IHC) was performed by an indirect streptavidin-biotin-peroxidase method as previously described [23] . The antibodies used were: (1) antip53 (DO-7 class, IgG2b mouse monoclonal; epitope, residues 1-45 of p53; 1:100 dilution) (Dako, Kalifronas, Greece) and (2) anti-Ki-67 (MIB-1) (class, IgG1 mouse monoclonal; epitope, Ki-67 nuclear antigen; 1:100 dilution) (Dako, Kalifronas, Greece). Tdt-mediated dUTP nick end labeling assay Tdt-mediated dUTP nick end labeling assay was performed according to a previously described protocol [23, 24] .
Statistical analysis
Analysis of variance (ANOVA), Pearson's chi-square (χ 2 ), Fisher's exact test, and t test analyses were used to explore molecular results and the correlations with the clinicopathological data, correspondingly. Kruskal-Wallis and MannWhitney tests were used in case of violation of normality. The associations between ICAM-1 polymorphism status and overall survival were estimated using the method of Kaplan-Meier and assessed using the log-rank test, and univariate and multivariate Cox regression models were developed to evaluate the effect of ICAM-1 genotypes on survival. The overall survival time was from 2003 to 2008, starting from the date of surgery (up to 67 months). At the end of the follow-up period, 32 of the 203 patients were still alive. Median follow-up after tumor resection for the 91 patients censored was 62 months (range, 3-83). Median recurrence survival was 41 months for the whole group. All statistical testing was done at the two-sided .05 level, and SPSS software version 16.00 was used.
Results
The ICAM-1 genotype and allele distribution was not significantly different in NSCLC patients compared to controls Neither the distribution of genotypes nor of alleles was found to be significantly different between patients and controls (p00.091) ( Table 2 ). The distribution of genotypes was consistent with the Hardy-Weinberg equilibrium in both patients and controls (p>0.05).
The AG/GG genotypes are significantly associated with worse survival and tend to be more frequently found in non-operable stages
Although there was no correlation between the genotype and most of the patient-and tumor-related parameters, i.e., age, smoking status, tumor size, metastasis status, histology (squamous vs adenocarcinoma), and grade (data not shown), there was a statistical trend observed in relation to lymph node status (p00.07, Fisher's exact test; data not shown).
Univariate and multivariate (adjusted for age, stage, tumor grade, and p53 status) Cox regression models were developed to evaluate the effect of ICAM-1 genotypes on overall survival for NSCLC patients (Table 3) . These regression models demonstrated a strong trend for an increase in risk for death in patients with the AG/AA genotype compared to those with the GG genotype. The unfavorable Fig. 1 a Survival curves performed by log-rank test on Kaplan-Meier estimates of survival in relation to ICAM-1 K469E SNP status in all stages of NSCLC. The presence of the AG/AA genotypes in NSCLC patients was significantly associated with worse prognosis (p00.036, log-rank test). b Bar plot depicting the statistical trend toward increased frequency of presence of the AG/ AA genotypes in advanced nonoperable stages of patients with NSCLC (p00.057, Fisher's exact test) overall survival rate of AG/AA patients relative to those of GG patients was also shown by Kaplan-Meier survival analysis (Fig. 1a) ; patients carrying the A allele had statistically significant worse survival (39 months) compared to the patients with the GG genotype (45 months; p00.036, log-rank test). Interestingly, there was a strong trend toward increased frequency of the AG/GG genotypes in nonoperable stages (p00.057, Fisher's exact test; Fig. 1b ).
The AA/AG genotypes exert a synergistic effect with aberrant p53 expression on tumor progression in NSCLC Since ICAM-1 is known to be involved in cell signaling [14] , we investigated whether the relative higher frequency of the GG genotype in operable NSCLC patients (91 patients) was related to tumor kinetics, as tissue biopsies only for these patients were available. There was no significant relation between the genotypes and PI and AI values or with the tumor growth index (GI: PI/AI; data not shown). However, given that ICAM-1 expression can be induced directly by p53 in an NF-kB-independent manner [17] and that there is different sensitivity to apoptosis between the ICAM-1 genotypes, we also investigated possible coassociations between the ICAM-1 K469E SNP and p53 status in relation to the tumor growth kinetics and clinicopathologic data in patients with operable NSCLC. As previously described [24] , due to the high correlation between p53 immunoreactivity and the presence of mutations, positive IHC results were considered as an indication of TP53 gene aberrations. As expected, the majority of the patients in both GG and AG/AA groups had aberrant expression of p53 (68.4 and 68.6 % respectively), which was not significantly different between the two groups.
All cases were stratified in four groups according to p53 and the ICAM-1 K469E SNP status, respectively ( Table 4) . The frequencies of these patterns indicate that in NSCLC, there was no mutual exclusion between p53 aberrant expression and the presence of any allele (p00.78, χ 2 test). No significant differences between the four groups in relation to the PI were obtained (p00.559). Nevertheless, a comparison of the AI between the four groups revealed a gradual decrease in the AI from the [p53(N)-AG/AA] group to the [p53(P)-AG/AA] one (Table 4) . Although this gradual decrease in the AI was not significant between consecutive Fig. 2 Fig. 2a ; Table 4 ). This result suggests that in the AG/AA background, there was a statistically significant decline in AI when p53 was not functional, while such a decline was not significant in the GG background, further implying a synergistic effect from p53 inactivation within the AG/AA background on AI in NSCLC. Similar results were also obtained in relation to the GI of the tumors (p00.026, 95 % CI (18.26-29.39), ANOVA-Bonferroni multiple comparisons; data not shown).
To further validate these results, we also examined the four patterns in relation to the stage of the patients; we combined stages II and IIIA as there were few patients with IIIA operable stage. Again, the [p53(P)-AG/AA] pattern was significantly more frequent in patients with stage II-IIIA compared to other patterns (p00.046, χ 2 test; Fig. 2b ).
Discussion
Recent studies have shown that ICAM-1 has significant implications in tumorigenesis and metastasis [4, 5] . While several genetic polymorphisms have been indentified in ICAM-1, a frequently investigated one in several types of cancer involves the g.1548A>G (K469E) SNP, due to its functional implications in the ICAM-1 protein ( Table 5) . As it has not been yet studied in NSCLC, we aimed to investigate whether this SNP may be associated with the development and/or progression of NSCLC. Our analysis did not confirm any association of the genotypes or alleles of this SNP with NSCLC risk. Studies of this SNP in various types of cancers have demonstrated disparate results, with most of them showing no difference in susceptibility to carcinogenesis [18] [19] [20] 27] . Notable is the fact that even studies that showed a statistically significant difference in frequency of alleles or genotypes had either opposite results-with the G allele being significant in familial cases of prostate cancer in one study [22] versus the A allele in breast and prostate cancer in another study [28] -or was observed in a subpopulation with specific characteristics (e.g., in grade II astrocytomas) [21] (Table 5) . We found that the variant A allele was associated with significantly worse survival among NSCLC patients, and in accordance, there was a trend toward increased frequency of the AG/GG genotypes in non-operable stages, suggesting that this allele may be associated with increased metastatic potential. This finding is biologically plausible, especially in light of the putative function of this polymorphism; it may affect the production of various ICAM-1 isoforms [14] and consequently may influence functionally ICAM-1 expression [10] . Table 5 Comparison of the ICAM-1 K469 SNP genotype frequencies in cases and controls in this study and previously published studies As this SNP is located within the 5′ splice donor site, it significantly affects splicing and contributes to transcriptome differences [29] . The G allele exhibits more difficulty in splicing to ICAM-1-S compared to the A allele [14] . ICAM-1-S lacks transmembrane and intracellular domain, which is crucial for efficient transendothelial adhesion [30] and migration of lymphocytes [31] , as well as effective antigen recognition and cytolytic abilities of T cells [14, 32] . Moreover, as it is soluble, it may compete with membrane ICAM-1 for β2-integrin binding, hence further inhibiting leukocyte recruitment trafficking [9] ; indeed, the sICAM-1 production in microvascular endothelial cells of the lung is partially mediated by the alternative splicing [9] . It was recently shown that the G allele is associated with increased expression of ICAM-1 on endothelial cells, which consequently can lead to increased adhesion of leukocytes [15] , while in another study, the A variant was found to be associated with increased levels of plasma sICAM-1 [16] . Taken together, it appears that within an AG or AA genetic environment, the increased production of ICAM-1-S causes defects in the leukocytes' functions [30, 31] , which can ultimately lead to defective immunosurveillance, shortened dormancy of disseminated tumor cells [32] , stimulation of angiogenesis [4, 33] , and genetic instability [23] .
Considering that ICAM-1-S can alter intracellular signal transduction [1] , the genotypes may have different impact on apoptosis [14] , and as ICAM-1 expression is regulated by p53 [17] , we investigated for possible co-associations between the genotypes and p53 in relation to tumor growth kinetics. We observed a statistically significant difference in the AI value after stratifying the cases upon patterns of p53 status and the ICAM-1 K469E SNP genetic background. Specifically, all genotypes presented lower AI values on an aberrant p53 background in accordance with the established role of p53 as intracellular "guardian" [34] . Nevertheless, the statistically significant decline in AI that was observed in patients with AG or AA genotype and aberrant p53 expression, which is in agreement with Iwao et al. showing that apoptosis may be more potent with the GG genotype [14] , emphasizes the functional relationship of p53 and ICAM-1 [17] , during which induction of ICAM-1 by p53 enhances the adhesion-dependent apoptotic mechanism.
Overall, when p53 is inactivated, the AG and AA genotypes confer synergistically to defective apoptosis. In support to this is the frequent presence of the AG and AA genotypes in patients with stages II and IIIA, while most patients with stage I carried the GG genotype, suggesting that an AG or AA genotype possibly contributes to higher metastatic potential of malignant cells. Consequently, poorly adherent cells with impaired apoptosis are more able to escape defective immunosurveillance in an AG or AA host background [35] and gradually may become an ideal target for further accumulation of mutations, which could eventually accelerate cancer progression via metastases outgrowth in a genetic environment that promotes invasion and angiogenesis [4, 17, 32, 33, 36] .
Our study has several limitations; it is retrospective, and because of the relatively small patient population analyzed, our findings should be interpreted with caution and require validation in subsequent studies. Although this polymorphism has known biological plausibility, though debatable, a comprehensive approach would incorporate other described polymorphisms as well as haplotype-tagging SNPs, in order to more fully characterize the ICAM-1 role, thus avoiding false-positive observations. Moreover, further biochemical studies are required to clarify the effect of this ICAM-1 SNP on gene transcription and protein function.
In conclusion, our results showed no role for the ICAM-1 K469E SNP in susceptibility to NSCLC development. However, the AG and AA genotypes are associated with worse prognosis and tend to present in advanced stages, providing a host background that offers survival advantage to malignant cells, most probably due to impaired immunosurveillance and apoptosis, which is reinforced when p53 is aberrantly expressed. The GG genotype retains a better apoptotic index, when p53 is non-functional, and may reflect a tumorigenic barrier left in these cells.
